Advertisement

Muscarinic and Nicotinic Mechanisms of Seizures Induced by Cholinesterase Inhibitors: Observations on Diazepam and Midazolam as Antagonists

  • Edward F. Domino
  • Ante Simonic
  • Halina Krutak-Krol

Abstract

The gross behavioral and EEG seizure-inducing effects of various cholinesterase inhibitors (ChEI) were compared to the cholinergic agonists arecoline and nicotine, and the classic convulsants pentylenetetrazol and strychnine in unanesthetized rats. It was also our purpose to determine the possible anticonvulsant activity of potential antagonists. Femoral arterial and venous cannulae, EEG (epidural) and EKG (Lead II) electrodes were surgically implanted under halothane-oxygen anesthesia into adult Sprague-Dawley male rats (200–350 gm). Upon recovery from halothane anesthesia each rat received one of the following: 1) a directly acting cholinergic agonist (arecoline or nicotine); 2) a cholinesterase inhibitor, diethyi-p-nitrophenylphosphate (paraoxon), diisopropylfluorophosphate (DFP), neostigmine, or physostigmine; or 3) a central nervous system convulsant (pentylenetetrazol or strychnine).

Each drug was administered i. v. in logarithmic cumulative doses until the animal exhibited tremors, major motor or cortical EEG seizures, and/or died. All of the cholinergic agonists, including the ChEIs, induced motor tremors. Nicotine produced convulsions, observed in the EEG and gross behavior, while arecoline did not cause cortical EEG or gross behavioral seizures but did produce aberrant body movements. Neostigmine, even in supralethal doses, did not elicit motor or EEG seizures. Physostigmine, in sublethal doses, caused abnormal motor movements with EEG desynchronization. Supralethal doses of physostigmine or the irreversible ChEI paraoxon produced EEG convulsive patterns. Sublethal doses of DFP yielded similar effects. The ChEI seizure activity was partially antagonized by atropine. The nicotinic antagonists mecamylamine, pempidine, or trimethidinium did not alter the ChEI-induced EEG seizure patterns. Pentylenetetrazol produced both gross behavioral and EEG seizures, while strychnine in convulsant doses produced only EEG desynchronization. Supralethal doses of strychnine did induce EEG seizures.

Midazolam was an effective anticonvulsant against all of the convulsants, especially when the induced EEG seizures were recorded in ventilated animals. Nicotine-induced seizures were not only not antagonized by atropine, but were enhanced. Since atropine partially antagonized ChEI induced seizures, it is concluded that both a muscarinic cholinergic as well as a non-cholinergic mechanism is involved.

A comparison was made between diazepam and midazolam given i. m. in antagonizing 2 x LD50 of s. c. paraoxon in the presence of 10 mg/kg atropine. Both benzodiazepines were effective in reducing paraoxon induced seizures and death. However, midazolam was more potent.

Keywords

Muscarinic Receptor Sublethal Dose Cholinergic Agonist Motor Seizure Muscarinic Receptor Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abood, L.G., Lowy, K., Tometsko, A., and MacNeil, M., 1979, Evidence for a noncholinergic site for nicotine’s action in brain: psychopharmacological, electrophysiological and receptor binding studies. Arch. Int. Pharmacodyn. Ther. 237 213–229.PubMedGoogle Scholar
  2. Andersen, P., Eccles, J.C., Loyning, Y., and Voorhoeve, P.E., 1963, Strychnine-resistant central inhibition. Nature 200: 843–845.PubMedCrossRefGoogle Scholar
  3. Bebbington, A., Brimblecombe, R.W., and Shakeshaft, D., 1966, The central and peripheral activity of acetylenic amines related to oxotremorine. Br. J. Pharmacol. 26: 56–67.Google Scholar
  4. Birdsall, N.J.M., Burgen, A.S.V., and Hulme, E.C., 1978a, Correlation between the binding properties and pharmacological responses of muscarinic receptors. in Cholinergic Mechanisms and Psychopharmacology, Vol. 24, D.J. Jenden, ed., Plenum Press, New York.Google Scholar
  5. Birdsall, N.J.M., Burgen, A.S.V., and Hulme, E.C., 1978b, The binding of agonists to brain muscarinic receptors. Mol. Pharmacol, 14: 723–736.PubMedGoogle Scholar
  6. Birdsall, N.J.M., Burgen, A.S.V., and Hulme, E.C., 1979, Multiple classes of muscarinic receptor binding sites in the brain. in Receptors: Advances in Pharmacology and Therapeutics: Proceedings of the Seventh International Congress of Pharmacology, Vol. 1, J. Jacob, ed., Pergamon Press, Oxford.Google Scholar
  7. Biscoe, T.J., and Curtis, D.R., 1967, Strychnine and cortical inhibition. Nature 214: 914–915.PubMedCrossRefGoogle Scholar
  8. Bradley, P.B. and Elkes, J., 1953, The effect of atropine, hyoscyamine, physostigmine, and neostigmine on the electrical activity of the brain of the conscious cat. J. Physiol. 120: 14P–15 P.PubMedGoogle Scholar
  9. Bradley, P.B. and Elkes, J., 1957, The effects of some drugs on the electrical activity of the brain. Brain 80: 77–117.PubMedCrossRefGoogle Scholar
  10. Brimblecombe, R.W., ed., 1974, Drug Actions on Cholinergic Systems, pp. 66–215, University Park Press, Baltimore.Google Scholar
  11. Chen, G. and Bohner, B., 1957, Antagonism of nicotine and some CNS depressants in mice. Fed. Proc. 16: 288.Google Scholar
  12. Cornblath, D.R. and Ferguson, 1976, Distribution of radioactivity from topically applied (H3) acetylcholine in relation to seizure. Exp. Neurol. 50: 495–504.PubMedCrossRefGoogle Scholar
  13. Costa, E., Guidotti, A., Mao, C.C. and Suria, A., 1975, New concepts on the mechanism of action of benzodiazepines. Life Sci. 17: 167–186.PubMedCrossRefGoogle Scholar
  14. Curtis, D.R., Duggan, A.W., and Johnston, G.A.R., 1971, The specificity of strychnine as a glycine antagonist in the mammalian spinal cord. Exp. Brain Res. 12: 547–565.PubMedCrossRefGoogle Scholar
  15. Davies, J. and Polc, P., 1978, Effect of a water soluble benzodiazepines on the response of spinal neurones to acetylcholine and excitatory amino acid analogues. Neuropharmacol. 17: 217–220.CrossRefGoogle Scholar
  16. De Jong, R.H. and Bonin, J.D., 1981, Benzodiazepines protect mice from local anesthetic convulsions and death. Anesth. Analg. 60: 385–389.PubMedGoogle Scholar
  17. Domino, E.F., 1967, Electroencephalographic and behavioral arousal effects of small doses of nicotine: a neuropsychopharmacological study. Ann. N.Y. Acad. Sci. 142: 216–244.CrossRefGoogle Scholar
  18. Domino, E.F., Simonic, A., and Krutak-Krol, H., 1985, Comparative muscarinic and nicotinic cholinergic mechamisms involved in seizures induced by cholinesterase inhibitors. Fifth Annual Chemical Defense Bioscience Review, Speakers Abstract pg. 29, U.S. Army Medical Research Institute of Chemical Defense, Columbia, MD.Google Scholar
  19. Dundee, J.W., 1979, New i. v. anaesthetics. Br. J. Anaesth. 51: 641–648.PubMedCrossRefGoogle Scholar
  20. Eccles, J.C., 1964, The Physiology of Synapses, pp. 1–316, Springer-Verlag, Berlin.CrossRefGoogle Scholar
  21. Esplin, D. and Zablocka-Esplin, B., 1969, Mechanism of action of convulsants. in Basic Mechanisms of Epilepsy, H.H. Jasper, A.A. Ward, and H. Pope, eds., Little Brown and Co., Boston.Google Scholar
  22. Evans, R.H., 1978, Cholinoceptive properties of motoneurones of the immature rat spinal cord maintained in vitro. Neuropharmacol. 17: 277–279.CrossRefGoogle Scholar
  23. Feher, O., Halasz, PR and Mechler, F., 1965, The mechanism of origin of cortical convulsive potentials. EEG Clin. Neurophysiol. 19: 541–548.CrossRefGoogle Scholar
  24. Granacher, R.P. and Baldessarini, R.J., 1975, Physostigmine. Arch. Gen. Psych. 32: 375–380.CrossRefGoogle Scholar
  25. Guidotti, A., 1978, Synaptic mechanisms in the action of benzodiazepines. in Psychopharmacology: A Generation of Progress, M. A. Lipton, A. Di Mascio, A., and K.F. DiPalma, eds., Raven Press, New York.Google Scholar
  26. Hulme, E.C., Birdsall, N.J.M., Burgen, A.S.V., and Mehta, P., 1978, The binding of antagonists to brain muscarinic receptors. Mol. Pharmacol. 14: 737–750.PubMedGoogle Scholar
  27. Huot, Jr Radouco-Thomas, S., and Radouco-Thomas, C., 1973, Qualitative and quantitative evaluation of experimentally induced seizures (pentetrazol induced seizures). in International Encyclopedia of Pharmacology and Therapeutics, Sec. 19, Vol. I, C. Radouco-Thomas, ed., Pergamon Press, New York.Google Scholar
  28. Karis, J.H. and Gissen, A.J., 1971, Evaluation of new neuromuscular blocking agents. Anesthesiology 35: 149–157.PubMedCrossRefGoogle Scholar
  29. Klemm, W.R., ed., 1969, Animal Electroencephalography, pp. 41–48, Academic Press, New York.Google Scholar
  30. Krnjevic, K., 1965, Cholinergic innervation of the cerebral cortex, in: D.R. Curtis and A.K. McIntyre, eds., Studies in Physiology, Springer Verlag, Berlin.Google Scholar
  31. Krutak-Krol, H., Simonie, A., and Domino, E.F., 1984, Comparative muscarinic and nicotinic cholinergic mechanisms in inducing EEG and major motor seizures in the rat. The Pharmacologist 26: 118.Google Scholar
  32. Larson, P.S., Haag, H.B., and Silvette, H., ed., 1961, Tobacco Experimental and Clinical Studies, Williams and Wilkins Co., Baltimore.Google Scholar
  33. Longo, V.G., ed., 1962, Electroencephalographic Atlas For Pharmacological Research, Rabbit Brain Research II, Elsevier, Amsterdam.Google Scholar
  34. Longoni, R., Mulas, A., Oderfeld-Novak, B., Marconcini-Pepeu, I., and Pepeu, G., 1976, Effect of single and repeated electroshock applications on brain acetylcholine levels and choline acetyltransferase activity in the rat. Neuropharmacol. 15: 283–286.CrossRefGoogle Scholar
  35. Lundy, P.M. and Shih, T.M., 1983, Examination of the role of central cholinergic mechanisms in the therapeutic effects of HI-6 in organophosphate poisoning. J. Neurochem. 40: 1321–1328.PubMedCrossRefGoogle Scholar
  36. Mao, C.C., Guidotti, A., and Costa, E., 1975, Evidence for an involvement of GABA in the mediation of the cerebellar cGMP decrease and the anticonvulsant action of diazepam. Naunyn-Schmied. Arch. Pharmacol. 289: 369–378.CrossRefGoogle Scholar
  37. Pellegrino, L.J., Pellegrino, A.S., and Cushman, A.J., eds., 1979, A Stereotaxic Atlas of the Rat Brain, Plenum Press, New York.Google Scholar
  38. Pfeiffer, C.C., Riopelle, A.J., Smith, R.P., Jenney, E.H., and Williams, H.L., 1957, Comparative study of the effects of meprobamate on the conditioned response, on strychnine and pentylenetetrazol thresholds, on the normal electroencephalogram, and on polysynaptic reflexes. Ann. N.Y. Acad. Sci. 67: 734–745.PubMedCrossRefGoogle Scholar
  39. Pope, A., Morris, A.A., Jasper, H., Eliott, K.A.C., and Penfield, W., 1947, Historical and action potential studies on epileptogenic areas of cerebral cortex in man and the monkey. Res. Publ. Assn. Nerv. Ment. Pis. 26: 218–231.Google Scholar
  40. Preston, J.B., 1955, Pentylenetetrazole and thiosemicarbazide: a study of convulsant activity in the isolated cerebral cortex preparation. J. Pharmacol. Exp. Ther. 115: 28–38.PubMedGoogle Scholar
  41. Richter, D. and Crossland, J., 1949, Variation in acetylcholine content of the brain with physiological state. Amer. J. Physiol. 159: 247–255.PubMedGoogle Scholar
  42. Romano, C. and Goldstein, A., 1980, Stereospecific nicotine receptors on rat brain membranes. Science 210: 647–650.PubMedCrossRefGoogle Scholar
  43. Shih, T.M., 1982, Time course effects of soman on acetylcholine and choline levels in six discrete areas of the rat brain. Psychopharmacology. 78: 170–175.PubMedCrossRefGoogle Scholar
  44. Silvette, H., Hoff, E.C., Larson, P.S., and Haag, H.B., 1962, The actions of nicotine on central nervous system functions. Pharmacol. Rev. 14: 137–173.PubMedGoogle Scholar
  45. Simonie, A., Krutak-Krol, H., and Domino, E.F., 1983, Muscarinic and nicotinic cholinergic mechanisms involved in seizures induced by Cholinesterase inhibitors (ChEI). Second International Meeting on Cholinesterases. Fundamental and Applied Aspects, pp. 159, Bled, Yugoslavia.Google Scholar
  46. Simonic, A., Krutak-Krol, H., and Domino, E.F., 1985, Comparative muscarinic and nicotinic cholinergic mechanisms involved in seizures induced by cholinesterase inhibitors. Fifth Annual Chemical Defense Bioscience Review, U.S. Army Research Institute of Chemical Defense, Columbia, MD.Google Scholar
  47. Sivam, S.P., Norris, J.C., Lim D.K., Hoskins, B., and Ho, I.K., 1983, Effect of acute and chronic cholinesterase inhibition with diisopropylfluorophosphate on muscarinic, dopamine and GABA receptors of the rat striatum. J. Neurochem. 40: 1414–1422.PubMedCrossRefGoogle Scholar
  48. Sloan, J.W. and Martin, W.R., 1984, SAR studies of pyridine (P), piperidine (PIP), and pyrrolidine (PY) analogs altering (±)-[3H] nicotine (Ni) binding in the rat brain P2 fraction. Fed. Proc. 43: 547.Google Scholar
  49. Spinks, A., Young, E.H.P., Farrington, J.A., and Dunlop, D., 1958, The pharmacological actions of pempidine and its ethyl homologue. Br. J. Pharm. 13: 501–520.Google Scholar
  50. Stone, C.A., Mecklenberg, K.L., and Torchiana, M.L., 1958, Antagonism of nicotine-induced convulsions by ganglionic blocking agents. Arch. Int. Pharmacodyn. Ther. 117: 419–434.PubMedGoogle Scholar
  51. Szreniawski, Z., Kostowski, W., Meszaros, J., Gajewska, S., Faff, J., Bak, W., and Rump, S., 1977, Central anticholinergic effects of N-ethyl-2-pyrrolidylmethyl-cyclopentylphenyl glycollate. Arch. Int. Pharmacodyn. Ther. 226: 302–312.PubMedGoogle Scholar
  52. Tarakhovsky, M.L., 1957, Central nicotinolytic action of a new ganglio-blocking substance, hexoniate. Pharmacol. & Toxicol. 20: 246–250.Google Scholar
  53. Van Meter, W.G., Karczmar, A.G., and Fiscus, R.R., 1978, CNS effects of anticholinesterases in the presence of inhibited cholinesterases. Arch. Int. Pharmacodyn. Ther. 231: 249–260.PubMedGoogle Scholar
  54. Zbinden, G. and Randall, L.O., 1967, Pharmacology of benzodiazepines: Laboratory and clinical correlations. Adv. Pharmac. 5: 213–291.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Edward F. Domino
    • 1
  • Ante Simonic
    • 1
    • 2
  • Halina Krutak-Krol
    • 1
  1. 1.Department of PharmacologyUniversity of MichiganAnn ArborUSA
  2. 2.Department of PharmacologyUniversity of RijekaRijekaYugoslavia

Personalised recommendations